Low molecular weight heparin for the treatment of retinal vein occlusion: A systematic review and meta-analysis of randomized trials

Haematologica

Volumn 95, Issue 9, 2010, Pages 1587-1593

  Lazo Langner, Alejandro ^a   Hawel, Jeff ^a   Ageno, Walter ^b   Kovacs, Michael J ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Aspirin; Low molecular weight heparin; Meta analysis; Retinal vein occlusion; Systematic review

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; BEMIPARIN; CERTOPARIN; DALTEPARIN; DICOUMAROL; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PHENPROCOUMON; REVIPARIN; TINZAPARIN; WARFARIN;

ARTICLE; BLEEDING; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; HEMATURIA; HUMAN; IRIS DISEASE; META ANALYSIS; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); RETINA VEIN OCCLUSION; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VEIN THROMBOSIS; VISUAL ACUITY; VISUAL FIELD DEFECT; VITREOUS HEMORRHAGE;

ASPIRIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77956830491     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.023614     Document Type: Article

References (42)

1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-41.
2. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513-8.
3. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006;124(5): 726-32.
4. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114(10):1243-7.
5. O'Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126(5):692-9.
6. Sperduto RD, Hiller R, Chew E, Seigel D, Blair N, Burton TC, et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: The eye disease casecontrol study. Ophthalmology. 1998;105(5):765-71.
7. Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Klein BE, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 populationbased cohorts. Ophthalmology. 2007; 114(3):520-4.
8. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A metaanalysis of thrombophilic factors. Thromb Haemost. 2005;93(6):1021-6.
9. The Central Vein Occlusion Study Group. Natural History and Clinical Management of Central Retinal Vein Occlusion. Arch Ophthalmol. 1997;115(4):486-91.
10. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007;114(5): 835-54.
11. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007;114(3): 507-19.
12. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-8.
13. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):454S-545.
14. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):199S-233S.
15. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl): 630S-69S.
16. Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA. Acute STSegment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl): 708S-75S.
17. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, et al. Antithrombotic Therapy for Non-STSegment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):670S-707S.
18. Sobel M, Verhaeghe R. Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):815S-43S.
19. Vignoli A, Marchetti M, Balducci D, BarbuiT, Falanga A. Differential effect of the lowmolecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica. 2006;91(2):207-14.
20. Ranjbaran H, Wang Y, Manes TD, Yakimov AO, Akhtar S, Kluger MS, et al. Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation. 2006;114(12):1293-300.
21. Boyden RC, Kettering HA. Occlusion of the central retinal vein; report of a case treated with heparin. US Nav Med Bull. 1948; 48(6):912.
22. Romanowska B, Goszcz A, Grodzinska L, Bieron K, Kostka-Trabka E. [Evaluation of fraxiparine efficacy in the treatment of retinal vein occlusion]. Klin Oczna. 1999; 101(6):451-4.
23. Kasymova MS. [Results of fraxiparin and ticlid therapy of acute retinal vessels occlusion]. Vestn Oftalmol. 1998;114(4):21-4.
24. Dona A, Sartori M, Piermarocchi S, Pilotto E, Pasetto L, Pagnan A, et al. Efficacy of early antithrombotic treatment in retinal vein occlusion. J Thromb Haemost. 2009;7 (Suppl 2): Abstract PP-MO-424.
25. Schulman S, Kearon C. Definition of majorbleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4): 692-4.
26. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
27. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359 (9306):614-8.
28. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006;59(1):7-10.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88.
30. Altman DG, Deeks JJ, Sackett DL. Odds ratios should be avoided when events are common. Br Med J. 1998;317(7168):1318.
31. Baker SG, Kramer BS. Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomes. BMC Med Res Methodol. 2003;3:10.
32. Deeks JJ, Altman DG, Dooley G, Sackett DL. Choosing an appropriate dichotomous effect measure for meta-analysis: empirical evidence of the appropriateness of the odds ratio and relative risk. Control Clin Trials. 1997;18 (3 Suppl):84S-5S.
33. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21(11):1575-600.
34. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-48.
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58.
36. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Version 2.3. www.OpenEpi.com. Atlanta: Rollins School of Public Health, Emory University; 2009.
37. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
38. Farahvash MS, Farahvash MM, Moradimogadam M, Mohammadzadeh S. Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. Arch Iran Med. 2008;11(5):539-43.
39. Ageno W, Cattaneo M, Manfredi E, Ghirarduzzi A, Filippucci E, Scannapieco G, et al. LMWH vs. aspirin for the treatment of acute retinal vein occlusion. J Thromb Haemost. 2009;7(Suppl 2): Abstract OCTH- 011.
40. Ageno W, Cattaneo R, Manfredi E, Chelazzi P, Venco L, Ghirarduzzi A, et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res. 2009;[In press] doi:10.1016/j.thromres.2009.05.007.
41. Farahvash MS, Moghaddam MM, Moghimi S, Mohammadzadeh S. Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol. 2008;43(1): 79-83.
42. Farahvash MS, Moradimogadam M, Farahvash MM, Mohammadzadeh S, Mirshahi A. Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. Arch Iran Med. 2008;11(4):418-22.